Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Part of paid clinical trials in Princeton, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07079644
Status
Completed

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab + Relatlimab — BIOLOGICAL
    As per product label
  • Nivolumab + Ipilimumab — BIOLOGICAL
    As per product label
  • Immunotherapy monotherapy — BIOLOGICAL
    As per product label
  • BRAF/MEK inhibitors — DRUG
    As per product label

Study Details

The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy

Key Dates

Start date
Nov 29, 2024
Status verified
Jul 2025
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025

Study Design

Enrollment
678 participants (actual)

Arms

  • Arm: 1L Nivolumab + Relatlimab cohort
  • Arm: 1L Nivolumab + Ipilimumab cohort
  • Arm: 1L Immunotherapy monotherapy cohort
  • Arm: 1L BRAF/MEKs inhibitors cohort

Primary Outcome Measure

Demographics [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bristol Myers SquibbPrincetonNew Jersey08540-4715-

Find similar trials in Princeton, NJ

By research site
Bristol Myers Squibb· Princeton, NJ

Related Studies